Page 38 - Read Online

Sabol et al. J Cancer Metastasis Treat 2021;7:20 https://dx.doi.org/10.20517/2394-4722.2021.35 Page 15 of 15

86. Yamada T, Yamazaki H, Yamane T, et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors
and through stromal cells. Blood 2003;101:2227-34. DOI PubMed
87. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. Notch inhibits osteoblast differentiation and causes
osteopenia. Endocrinology 2008;149:3890-9. DOI PubMed PMC
88. Hilton MJ, Tu X, Wu X, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast
differentiation. Nat Med 2008;14:306-14. DOI PubMed PMC
89. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing
Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006;281:6203-10. DOI PubMed
90. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E. Notch 1 impairs osteoblastic cell differentiation. Endocrinology
2003;144:5631-9. DOI PubMed
91. Tezuka K, Yasuda M, Watanabe N, et al. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 2002;17:231-9.
DOI PubMed
92. Canalis E, Adams DJ, Boskey A, Parker K, Kranz L, Zanotti S. Notch signaling in osteocytes differentially regulates cancellous and
cortical bone remodeling. J Biol Chem 2013;288:25614-25. DOI PubMed PMC
93. Liu P, Ping Y, Ma M, et al. Anabolic actions of Notch on mature bone. Proc Natl Acad Sci U S A 2016;113:E2152-61. DOI PubMed
PMC
94. Marino S, Petrusca DN, Roodman GD. Therapeutic targets in myeloma bone disease. Br J Pharmacol 2019. DOI PubMed
95. Silbermann R, Roodman GD. Current controversies in the management of myeloma bone disease. J Cell Physiol 2016;231:2374-9.
DOI PubMed
96. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011;17:1278-
86. DOI PubMed
97. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia 2009;23:435-41. DOI PubMed
98. Colombo M, Thümmler K, Mirandola L, et al. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget
2014;5:10393-406. DOI PubMed PMC
99. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med
2011;17:1235-41. DOI PubMed PMC
100. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat
Med 2011;17:1231-4. DOI PubMed
101. Xu S, Evans H, Buckle C, et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma
patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 2012;26:2546-9. DOI PubMed
102. Guo J, Fei C, Zhao Y, et al. Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from
multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget 2017;8:55405-21. DOI PubMed PMC
103. Canalis E, Bridgewater D, Schilling L, Zanotti S. Canonical Notch activation in osteocytes causes osteopetrosis. Am J Physiol
Endocrinol Metab 2016;310:E171-82. DOI PubMed PMC
104. Schwarzer R, Kaiser M, Acikgoez O, et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia
2008;22:2273-7. DOI PubMed
105. Ferrari A, McAndrews K, Nelson JH, et al. Bone-targeted inhibition of Notch signaling blocks tumor growth and prevents bone loss
without inducing gut toxicity in immunodeficient and immunocompetent murine models of established multiple myeloma. J Bone
Miner Res 2019;34:32.
106. Moore G, Annett S, McClements L, Robson T. Top Notch targeting strategies in cancer: A detailed overview of recent insights and
current perspectives. Cells 2020;9:1503. DOI PubMed PMC
107. Fabbro D, Bauer M, Murone M, Lehal R. Notch inhibition in cancer: Challenges and opportunities. Chimia (Aarau) 2020;74:779-83.
DOI PubMed
108. Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
Drug Resist Updat 2008;11:210-8. DOI PubMed PMC
109. Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta
oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88. DOI PubMed
110. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61. DOI
PubMed
111. Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-
secretase inhibitor. J Biol Chem 2003;278:46107-16. DOI PubMed
112. Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the Notch transcription factor complex. Proc Natl Acad Sci U S A
2020;117:16292-301. DOI PubMed PMC
113. Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in
multiple myeloma. Blood 2019;134:1585-97. DOI PubMed PMC